moderate to severe Alzheimer'
Conditions
Interventions
Group A
At first, donepezil (10mg/day) for 24weeks continuously. Memantine is added at 5mg/day (W13)to 20mg/day at W16 (+5mg/day per every 1 week). As a result, donepezil (10mg/day) +memantine (20mg/day) from
At first, donepezil is fixed at 5mg/day continuously from W1 to W13. And from W14 to W24, donepezil is up to 10mg/day. Memantine start from W1 at 5mg/day and adding up to 20mg/day at W4 (+5mg/day per
Sponsors
YASUJI YAMAMOTO
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion Criteria:Diagnosed as Alzheimer's disease with DSM-4. Severity of dementia: FAST5-6. Medication: Donepezil 5mg/day >=6 months continuously as stable.
Exclusion criteria
Exclusion criteria: Patients with contraindication for donepezil or/and memantine. Patients who is judged as inappropriate for entry to this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| We will carry out tree contents of SIB, FAST and MMSE for 3 times at every 12 week-point during 24 weeks from the start-point of medication and evaluate the results of usefulness. | — |
Secondary
| Measure | Time frame |
|---|---|
| We will carry out two contents of NPI-D and ADCS-ADL for 3 times at every 12 week-point during 24 weeks from the start-point of medication and evaluate the results of usefulness. | — |
Countries
Japan
Contacts
Public ContactYASUJI YAMAMOTO
Kobe University Graduate School of Medicine Department of Psychiatry
Outcome results
None listed